Patients with GERD exhibit distinct acid–symptom phenotypes following acid suppression, suggesting a potential role for phenotype-guided disease management.
The relationship between esophageal acid exposure and symptom severity in gastroesophageal reflux disease (GERD) is often complex, with high levels of reflux potentially obscuring individual patterns of symptom perception. Against this backdrop, researchers examined whether suppressing post-meal acid exposure using omeprazole (proton pump inhibitors; PPIs) or ranitidine plus antacid could differentiate patient-specific acid–symptom profiles. They conducted two complementary clinical investigations using standardized meal-provocation testing in patients with GERD.
Following meal consumption, esophageal acid exposure and heartburn severity were systematically measured for 3 hours in the omeprazole cohort and 4.5 hours in the ranitidine-plus-antacid cohort. The data was subsequently analyzed using receiver operating characteristic methodology and phenotype-based stratification to characterize relationships between acid burden and symptom perception. Both omeprazole and ranitidine + antacid noticeably reduced post-meal esophageal acid exposure and heartburn severity, while revealing previously hidden differences in how patients experienced reflux symptoms.
Key findings included:
The findings suggest that symptom burden in GERD cannot always be explained solely by the degree of acid exposure. By diminishing esophageal acid levels, therapies such as omeprazole or ranitidine combined with antacid may reveal latent patient-specific patterns of reflux perception and symptom sensitivity. These phenotypes could help explain why some patients continue to experience symptoms despite adequate acid suppression, while others achieve substantial relief even when residual acid exposure persists.
Digestive Diseases and Sciences
Esophageal Acid Suppression Unmasks Latent Esophageal Acid-Symptom Phenotypes in GERD
Jerry D Gardner et al.
Comments (0)